NCT07251309招募中3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of WS016 in Patients With Hyperkalemia
Waterstone Pharmaceutical (Wuhan) Co., LTD.50 个研究点 分布在 1 个国家目标入组 420 人开始时间: 2024年12月23日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 420
- 试验地点
- 50
- 主要终点
- Mean serum potassium level during maintenance phase Days 8-29
研究概览
简要总结
This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase (MP). Part B (open-label extension, OLE) is an open-label, 11-month extension study carried out in participants who come from Part A and meet certain inclusion criteria.
详细描述
Eligible participants with hyperkalemia will first be randomized in a 5:1 ratio to receive oral WS016 (12g) or placebo three times daily, for a total of six doses over 48 hours.
After the 48-hour corrective treatment, participants whose serum potassium is within the normal range will be re-randomized in a 1:1:1:1 ratio to receive oral WS016 (6g, 12g, or 18g) or placebo once daily for 28 consecutive days.
Participants who complete the 28-day maintenance phase or prematurely discontinue from it due to hyperkalemia or hypokalemia, and who meet the eligibility criteria, will be eligible to enter Part B. In Part B, participants will receive WS016 for 11 months, starting at 12g once daily, with subsequent dose adjustments based on serum potassium levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (male or female) aged 18 years and older;
- •Participants with a serum potassium concentration >5.0 mmol/L and ≤6.5 mmol/L (serum potassium concentration will be measured using the i-STAT portable biochemical analyzer in screening period);
- •Participants who have negative pregnancy test result at screening and ensure the use of contraception during the trial;
- •Participants who understand and voluntarily sign the Informed Consent Form.
排除标准
- •Participants who have a history of severe drug allergy, or are definitely allergic to the investigational product or its ingredients;
- •Participants who have pseudohyperkalemia, such as serum potassium increasing caused by hemolysis of blood samples due to improper blood collection methods (such as too tight pressure pulse band banding, too heavy local rubbing, repeated fist clenching-loosening hands), hemolysis of blood samples due to difficulty in venipuncture or trauma, and severe leukocytosis (>50 × 10^9/L) or thrombocytosis (>500 × 10^9/L);
- •Participants with acute hyperkalemia caused by conditions such as tumor lysis syndrome or hemolysis and so on;
- •Participants suffering from severe cerebrovascular diseases, such as cerebral infarction or cerebral hemorrhagic disease, with language disorder or unresponsiveness, or severely blocked limb movement;
- •Participants who have suffered from myocardial infarction, or have undergone interventional cardiac procedures or coronary artery bypass grafting for coronary atherosclerotic heart disease within 3 months prior to screening; or participants who have heart failure and are in cardiac function class IV (New York Heart Association, NYHA classification criteria) at screening;
- •Participants with cardiac arrhythmia requiring urgent treatment at screening, such as ventricular tachycardia, ventricular fibrillation, II-III degree atrioventricular block, severe bradycardia (heart rate <40 bpm), or participants with significant prolongation of PR interval (PR interval prolonged to more than 0.25 seconds in the absence of pre-existing atrioventricular block), decrease or disappearance of P wave amplitude, and widening of QRS wave (widening to more than 0.14 seconds in the absence of pre-existing bundle branch block) indicated by the electrocardiogram at screening;
- •Participants who have previously undergone major gastrointestinal surgery such as subtotal gastrectomy, short bowel syndrome and other diseases affecting the normal peristalsis of the gastrointestinal tract; or participants with intractable constipation;
- •Participants who have received treatment with polypropylene exchange resin or sodium zirconium cyclosilicate and other similar drugs within 3 days before screening;
- •Participants who participated in other clinical trials of drugs or devices not approved for marketing within 3 months prior to the first dose;
- •Participants who are receiving dialysis;
- •Participants with severe hepatic impairment: serum alanine aminotransferase or aspartate aminotransferase more than 3 times the upper limit of normal;
- •Participants who are unable to complete this part of the trial as assessed by the investigator due to any other disease or psychiatric condition; or participants whose participation in the trial is assessed by the investigator as having a risk that far outweighs the benefit.
研究组 & 干预措施
WS016 (corrective phase)
Experimental
干预措施: WS016 (Drug)
Placebo (corrective phase)
Placebo Comparator
干预措施: Placebo (Drug)
WS016 (maintenance phase)
Experimental
干预措施: WS016 (Drug)
Placebo (maintenance phase)
Placebo Comparator
干预措施: Placebo (Drug)
WS016 (open-label extension phase)
Experimental
干预措施: WS016 (Drug)
结局指标
主要结局
Mean serum potassium level during maintenance phase Days 8-29
时间窗: Maintenance phase Days 8-29
次要结局
- Mean change from baseline in serum potassium at all time points of maintenance phase(Through 28 days maintenance phase)
- Percentage of participants with the mean serum potassium ≤5.0 mmol/L and percentage of participants with the mean serum potassium ≤5.5 mmol/L from D8 to D337 of the open-label extension phase(Open-label extension phase Days 8-337)
- Exponential rate of change in serum potassium during the corrective phase(Through 48 hours corrective phase)
- Mean change from baseline in serum potassium at all time points of corrective phase(Through 48 hours corrective phase)
- Cumulative duration (in days) of serum potassium within the normal range during the maintenance phase(Maintenance phase baseline to maintenance phase Day 29)
研究者
研究点 (50)
Loading locations...
相似试验
尚未招募
3 期
A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHBNCT07095855Shanghai Zhimeng Biopharma, Inc.1,300
已完成
3 期
A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)Canthal LinesNCT01308060Galderma R&D335
已完成
1 期
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's DiseaseHealthy ElderlyAlzheimer's DiseaseNCT06546995Neumora Therapeutics, Inc.87
终止
2 期
LYT-100 in Post-acute COVID-19 Respiratory DiseaseCovid19Post-acute COVID-19 Respiratory DiseaseNCT04652518PureTech185
已完成
1 期
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age InclusiveDermatitis, AtopicNCT05590338GlaxoSmithKline38